PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2023

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

GlobalData projects the global HIV marketplace — which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) — to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare’s Triumeq (dolutegravir/abacavir/lamivudine), Gilead’s Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Scope

Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline HIV market revenue from 2013–2023. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2013–2023?

What are the most promising late-stage pipeline drugs in HIV?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the unmet needs in HIV treatment management?

What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Companies mentioned

Gilead Sciences

ViiV Healthcare

AbbVie

Merck & Co.

Janssen

Bristol-Myers Squibb

Japan Tobacco

Avexa*

TaiMed Biologics*

Tobira Therapeutics*

Gilead Sciences

ViiV Healthcare

AbbVie

Merck & Co.

Janssen

Bristol-Myers Squibb

Japan Tobacco

Avexa*

TaiMed Biologics*

Tobira Therapeutics*

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology ...

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology

3.1.1Viral Lifecycle

3.2Pathophysiology

3.3Staging and Symptoms

3.3.1Primary or Acute Infection

3.3.2Chronic Infection

3.3.3Advanced Infection/AIDS

3.4Prognosis

3.5Quality of Life

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1US

4.3.25EU

4.3.3Brazil, China, and Japan

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods

4.5Epidemiological Forecast for HIV in the 8MM (2013–2023)

4.5.1Total Prevalent Cases of HIV

4.5.2Age-Specific Total Prevalent Cases of HIV

4.5.3Sex-Specific Total Prevalent Cases of HIV

4.5.4Age-Standardized Total Prevalence of HIV

4.5.5HIV Cases Treated with ART

4.5.6Cases of HIV in Pregnant Women

4.6Epidemiological Forecast for HIV in Japan (2013–2023)

4.6.120-Year Diagnosed Prevalent Cases of HIV

4.6.2Age-Specific 20-Year Diagnosed Prevalent Cases of HIV

4.6.3Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV

4.6.4Age-Standardized 20-Year Diagnosed Prevalence of HIV

4.6.5HIV Cases Treated with ART

4.6.6Cases of HIV in Pregnant Women

4.7Discussion

4.7.1Epidemiological Forecast Insight

4.7.2Limitations of the Analysis

4.7.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Screening and Diagnosis

5.1.2Treatment Guidelines and Leading Prescribed Drugs

5.1.3Clinical Practice

5.2US

5.2.1Screening and Diagnosis

5.2.2Clinical Practice

5.35EU

5.3.1Screening and Diagnosis

5.3.2Clinical Practice

5.4Japan

5.4.1Screening and Diagnosis

5.4.2Clinical Practice

5.5Brazil

5.5.1Screening and Diagnosis

5.5.2Clinical Practice

5.6China

5.6.1Screening and Diagnosis

5.6.2Clinical Practice

6Competitive Assessment

6.1Overview

6.2Product Profiles – Major Brands, Single-Tablet Regimens (STRs)

6.2.1Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

6.2.2Complera (emtricitabine/TDF/rilpivirine)

6.2.3Stribild (elvitegravir/cobicistat/TDF/emtricitabine)

6.2.4Triumeq (dolutegravir/abacavir/lamivudine)

6.3Product Profiles – Major Brands, Fixed-Dose Combinations

6.3.1Truvada (TDF/emtricitabine)

6.3.2Epzicom (abacavir/lamivudine)

6.3.3Kaletra (lopinavir/ritonavir)

6.3.4Prezcobix (darunavir/cobicistat)

6.3.5Evotaz (atazanavir sulfate/cobicistat)

6.4Product Profiles – Major Brands, Protease Inhibitors

6.4.1Reyataz (atazanavir)

6.4.2Prezista (darunavir)

6.5Product Profiles – Major Brands, Integrase Inhibitors

6.5.1Isentress (raltegravir)

6.5.2Tivicay (dolutegravir)

6.5.3Vitekta (elvitegravir)

6.6Product Profiles – Major Brands, Pharmacokinetic Enhancers

6.6.1Norvir (ritonavir)

6.6.2Tybost (cobicistat)

6.7Other Therapeutic Classes

6.7.1Entry Inhibitors

7Unmet Need and Opportunity

7.1Overview

7.2Therapies with Improved Safety and Tolerability Profiles

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Simplified PI-Based ART Regimens with a Reduced Pill Burden

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

7.6Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains

7.6.1Unmet Need

7.6.2Gap Analysis

7.6.3Opportunity

7.7Long-Acting Regimens That Require Less Frequent Administration

7.7.1Unmet Need

7.7.2Gap Analysis

7.7.3Opportunity

7.8Improved Access to Treatment

7.8.1Unmet Need

7.8.2Gap Analysis

7.8.3Opportunity

7.9Progress Towards a Functional Cure

7.9.1Unmet Need

7.9.2Gap Analysis

7.9.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Country

8.3Promising Drugs in Late-Stage Clinical Development

8.3.1Quad 2 (elvitegravir/cobicistat/emtricitabine/TAF)

8.3.2Darunavir/Cobicistat/Emtricitabine/TAF

8.3.3Emtricitabine/TAF

8.3.4Dutrebis (raltegravir/lamivudine)

8.3.5Doravirine (MK-1439)

8.4Promising Drugs in Early-Stage Clinical Development

8.5Other Drugs in Clinical Development

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Gilead Sciences

9.3.2ViiV Healthcare

9.3.3AbbVie

9.3.4Merck & Co.

9.3.5Janssen

9.3.6Bristol-Myers Squibb

9.3.7Japan Tobacco

9.3.8Avexa

9.3.9TaiMed Biologics

9.3.10Tobira Therapeutics

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2United States

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5Brazil

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

10.6China

10.6.1Forecast

10.6.2Key Events

10.6.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Total Prevalent Cases of HIV

11.4.220-Year Diagnosed Prevalent Cases of HIV

11.4.3HIV Cases Treated with ART

11.4.4Drugs Included in Each Therapeutic Class

11.4.5Launch and Patent Expiry Dates

11.4.6General Pricing Assumptions

11.4.7Individual Drug Assumptions

11.4.8Generic Erosion

11.4.9Pricing of Pipeline Agents

11.5Primary Research – KOLs Interviewed for This Report

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Analyst

11.7.2Epidemiologists

11.7.3Therapy Area Director

11.7.4Global Director of Therapy Analysis and Epidemiology

11.7.5Global Head of Healthcare

11.8About GlobalData

11.9Disclaimer

List of Tables

Table 1: Symptoms of HIV-1 Infection and AIDS

Table 2: Risk Factors and Comorbidities for HIV

Table 3: US, Total Prevalence of HIV in Men ...

Table 1: Symptoms of HIV-1 Infection and AIDS

Table 2: Risk Factors and Comorbidities for HIV

Table 3: US, Total Prevalence of HIV in Men and Women (%), Age =13 Years, 2006–2010

Table 4: 5EU, Total Prevalence of HIV in Men (%), All Ages, Selected Years, 2001–2013

Table 5: 5EU, Total Prevalence of HIV in Women (%), All Ages, Selected Years, 2001–2013

Table 6: 8MM, Sources Used to Forecast theTotal Prevalent Cases of HIV

Table 7: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan

Table 8: 9MM, Sources Used to Forecast the ART Treatment Rate Among the Total Prevalent Cases of HIV

Table 9: 9MM, Sources Used to Forecast the Prevalent Cases of HIV-Positive Pregnant Women

Table 10: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013–2023

Table 11: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N (Row %), 2013

Table 12: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N (Row %), 2013

Table 13: 8MM, HIV Cases Treated with ART, N (Col %), All Ages, Both Sexes, Selected Years 2013–2023

Table 14: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, Selected Years, 2013–2023

Table 15: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N (Row %), 2013

Table 16: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N (Row %), 2013

Table 17: Japan, HIV Cases Treated with ART, All Ages, Both Sexes, N, Selected Years 2013–2023

Table 18: Treatment Guidelines for HIV-1 Used in the 9MM

Table 19: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2013

Table 20: Diagnosis and Treatment of HIV Infection, Country Profile – US

Table 21: Switching of ART Regimens in the US, 2013

Table 22: Diagnosis and Treatment of HIV Infection, Country Profile – 5EU

Table 23: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU

Table 24: Switching of ART Regimens in the 5EU, 2013

Table 25: Diagnosis and Treatment of HIV Infection, Country Profile – Japan

Table 26: Switching of ART Regimens in Japan, 2013

Table 27: Diagnosis and Treatment of HIV Infection, Country Profile – Brazil

Table 28: Switching of ART Regimens in Brazil. 2013

Table 29: Diagnosis and Treatment of HIV Infection, Country Profile – China

Table 30: Switching of ART Regimens in China, 2013

Table 31: Leading Branded Treatments for HIV, 2013

Table 32: Product Profile – Atripla

Table 33: Antiviral Efficacy of Atripla Compared with Combivir-Efavirenz Combination Therapy

Table 34: Atripla’s Safety – Adverse Reactions Reported in a 144-Week Clinical Study

Table 35: Atripla SWOT Analysis, 2014

Table 36: Sales Forecasts ($m) for Atripla, 2013–2023

Table 37: Product Profile – Complera

Table 38: ECHO and THRIVE Studies of the Complera and Atripla Multi-Tablet Regimens

Table 39: Complera SWOT Analysis, 2014

Table 40: Sales Forecasts ($m) for Complera, 2013–2023

Table 41: Product Profile – Stribild

Table 42: Pivotal Phase III Trials of Stribild in Treatment-Na?ve Patients

Table 43: Stribild’s Adverse Reactions – Pooled Results From the Two Phase III Clinical Trials

Table 44: Stribild SWOT Analysis, 2014

Table 45: Sales Forecasts ($m) for Stribild, 2013–2023

Table 46: Product Profile – Triumeq

Table 47: Virologic Efficacy of Triumeq in the Phase III SINGLE Study

Table 48: Triumeq’s Safety – Adverse Reactions Reported at 96 Weeks in the SINGLE Study

Table 49: Triumeq SWOT Analysis, 2014

Table 50: Sales Forecasts ($m) for Triumeq, 2013–2023

Table 51: Product Profile – Truvada

Table 52: Truvada’s Efficacy – Results of the SWIFT Trial at 48 Weeks

Table 53: Truvada SWOT Analysis, 2014

Table 54: Sales Forecasts ($m) for Truvada, 2013–2023

Table 55: Product Profile – Epzicom

Table 56: Epzicom SWOT Analysis, 2014

Table 57: Sales Forecasts ($m) for Epzicom, 2013–2023

Table 58: Product Profile – Kaletra

Table 59: Kaletra SWOT Analysis, 2014

Table 60: Sales Forecasts ($m) for Kaletra, 2013–2023

Table 61: Product Profile – Prezcobix

Table 62: Efficacy of Prezcobix in the Phase III Trial

Table 63: Prezcobix SWOT Analysis, 2014

Table 64: Sales Forecasts ($m) for Prezcobix, 2013–2023

Table 65: Product Profile – Evotaz

Table 66: Efficacy of BMS’ Evotaz in the Phase III Study

Table 67: Evotaz SWOT Analysis, 2014

Table 68: Sales Forecasts ($m) for Evotaz, 2013–2023

Table 69: Product Profile – Reyataz

Table 70: Reyataz SWOT Analysis, 2014

Table 71: Sales Forecasts ($m) for Reyataz, 2013–2023

Table 72: Product Profile – Prezista

Table 73: Prezista SWOT Analysis, 2014

Table 74: Sales Forecasts ($m) for Prezista, 2013–2023

Table 75: Product Profile – Isentress

Table 76: Percentage of Patients with HIV-1 RNA Levels <50 Copies/mL from the SMARTMRK Study

Table 77: Isentress’ Safety – Adverse Reactions Reported in the SMARTMRK Study

Table 78: Isentress SWOT Analysis, 2014

Table 79: Sales Forecasts ($m) for Isentress, 2013–2023

Table 80: Product Profile – Tivicay

Table 81: Pivotal Phase III Trials of Tivicay

Table 82: Tivicay’s Safety – Adverse Reactions Reported in the 48-Week SINGLE Study

Table 83: Tivicay SWOT Analysis, 2014

Table 84: Sales Forecasts ($m) for Tivicay, 2013–2023

Table 85: Product Profile – Vitekta

Table 86: Efficacy of Vitekta in the Pivotal Phase III Clinical Study

Table 87: Vitekta’s Safety – Adverse Reactions Reported in the 96-Week Clinical Study

Table 88: Vitekta SWOT Analysis, 2014

Table 89: Sales Forecasts ($m) for Vitekta, 2013–2023

Table 90: Product Profile – Norvir (ritonavir)

Table 91: Norvir SWOT Analysis, 2014

Table 92: Sales Forecasts ($m) for Norvir, 2013–2023

Table 93: Product Profile – Tybost

Table 94: Efficacy of Tybost Versus Ritonavir as a Pharmacoenhancer of Atazanavir in the Phase III Trial

Table 95: Tybost SWOT Analysis, 2014

Table 96: Sales Forecasts ($m) for Tybost, 2013–2023

Table 97: Summary of the Minor Therapeutic Classes of EIs, 2014

Table 98: Unmet Need and Opportunity in HIV

Table 99: Promising Drugs in Clinical Development for HIV, 2014

Table 100: Comparison of Therapeutic Classes in Development for HIV, 2013–2023

Table 101: Gilead’s Quad 2 – Phase III Clinical Trials

Table 102: Product Profile – Quad 2

Table 103: Efficacy of Quad 2 and Stribild in Studies 104 and 111

Table 104: Adverse Events Associated with Quad 2 vs. Stribild Therapy in two Phase III Clinical Studies

Table 105: Renal and Bone Safety of Quad 2 Versus Stribild Treatment in the Two Pivotal Phase III Studies

Table 106: Quad 2 SWOT Analysis, 2014

Table 107: Sales Forecasts ($m) for Quad 2, 2013–2023

Table 108: Product Profile – Darunavir/cobicistat/emtricitabine/TAF

Table 109: Efficacy of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study

Table 110: Safety of Darunavir/Cobicistat/Emtricitabine/TAF – Adverse Reactions Reported at 48 Weeks in the Phase II Study

Table 111: Renal and Bone Safety of Darunavir/Cobicistat/Emtricitabine/TAF in the Phase II Study

Table 112: Darunavir/Cobicistat/Emtricitabine/TAF SWOT Analysis, 2014

Table 113: Sales Forecasts ($m) for Darunavir/Cobicistat/Emtricitabine/TAF, 2013–2023

Table 114: Product Profile – Emtricitabine/TAF

Table 115: Two Pivotal Clinical Trials of Emtricitabine/TAF

Table 116: Phase III Clinical Trials Assessing the Safety of Emtricitabine/TAF

Table 117: Emtricitabine/TAF SWOT Analysis, 2014

Table 118: Sales Forecasts ($m) for Emtricitabine/TAF, 2013–2023

Table 119: Product Profile – Dutrebis

Table 120: Percentage of Patients with HIV-1 RNA Levels of <50 Copies/mL in the SMARTMRK Study

Table 121: Dutrebis SWOT Analysis, 2014

Table 122: Sales Forecasts ($m) for Dutrebis, 2013–2023

Table 123: Product Profile – Doravirine

Table 124: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz

Table 125: Doravirine SWOT Analysis, 2014

Table 126: Sales Forecasts ($m) for Doravirine, 2013–2023

Table 127: Promising Drugs in Early-Stage Clinical Development for HIV, 2014

Table 128: Other Earlier-Stage Drugs in Active Clinical Development for HIV, 2014

Table 129: Key Companies in the HIV-1 Market in the 9MM, 2014

Table 130: Gilead Sciences’ HIV Portfolio Assessment, 2014

Table 131: Gilead Sciences, SWOT Analysis in HIV, 2013–2023

Table 132: ViiV Healthcare’s HIV Portfolio Assessment, 2014

Table 133: ViiV Healthcare, SWOT Analysis in HIV, 2013–2023

Table 134: AbbVie’s HIV Portfolio Assessment, 2014

Table 135: AbbVie, SWOT Analysis in HIV, 2013–2023

Table 136: Merck & Co.’s HIV Portfolio Assessment, 2014

Table 137: Merck & Co., SWOT Analysis in HIV, 2013–2023

Table 138: Janssen’s HIV Portfolio Assessment, 2014

Table 139: Janssen, SWOT Analysis in HIV, 2013–2023

Table 140: BMS’ HIV Portfolio Assessment, 2014

Table 141: BMS, SWOT Analysis in HIV, 2013–2023

Table 142: Japan Tobacco’s HIV Portfolio Assessment, 2014

Table 143: Japan Tobacco, SWOT Analysis in HIV, 2013–2023

Table 144: Avexa’s HIV Portfolio Assessment, 2014

Table 145: Avexa, SWOT Analysis in HIV, 2013–2023

Table 146: TaiMed Biologics, HIV Portfolio Assessment, 2014

Table 147: TaiMed Biologics, SWOT Analysis in HIV, 2013–2023

Table 148: Tobira Therapeutics, HIV Portfolio Assessment, 2014

Table 149: Tobira Therapeutics, SWOT Analysis in HIV, 2013–2023

Table 150: Global Sales Forecasts ($m) for HIV Therapeutics, 2013–2023

Table 151: Global HIV Therapeutics Market – Drivers and Barriers, 2013–2023

Table 152: Sales Forecasts ($m) for HIV Therapeutics in the US, 2013–2023

Table 153: Key Events Impacting Sales of HIV Therapeutics in the US, 2013–2023

Table 154: HIV Therapeutics Market in the US – Drivers and Barriers, 2013–2023

Table 155: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics, 2013

Table 156: Sales Forecasts ($m) for HIV Therapeutics in the 5EU, 2013–2023

Table 157: Key Events Impacting Sales of HIV Therapeutics in the 5EU, 2013–2023

Table 158: HIV Therapeutics Market in the 5EU – Drivers and Barriers, 2013–2023

Table 159: Financing of ART in the 5EU Countries by the National Healthcare Authorities

Table 160: Electronic Healthcare Systems Introduced in the 5EU Nations

Table 161: ART Initiation Criteria in the 5EU

Table 162: Systems Used to Control Drug Prices in the 55EU

Table 163: Sales Forecasts ($m) for HIV Therapeutics in Japan, 2013–2023

Table 164: Key Events Impacting Sales of HIV Therapeutics in Japan, 2013–2023

Table 165: HIV Therapeutics Market in Japan – Drivers and Barriers, 2013–2023

Table 166: Sales Forecasts ($m) for HIV Therapeutics in Brazil, 2013–2023

Table 167: Key Events Impacting Sales of HIV Therapeutics in Brazil, 2013–2023

Table 168: HIV Therapeutics Market in Brazil – Drivers and Barriers, 2013–2023

Table 169: Sales Forecasts ($m) for HIV Therapeutics in China, 2013–2023

Table 170: Key Events Impacting Sales of HIV Therapeutics in China, 2013–2023

Table 171: HIV Therapeutics Market in China – Drivers and Barriers, 2013–2023

Table 172: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM

Table 173: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM

Table 174: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

Figure 1: HIV Lifecycle

Figure 2: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013–2023

Figure 3: 8MM, Age-Specific Total ...

Figure 1: HIV Lifecycle

Figure 2: 8MM, Total Prevalent Cases of HIV, Men and Women, All Ages, N, 2013–2023

Figure 3: 8MM, Age-Specific Total Prevalent Cases of HIV, Men and Women, N, 2013

Figure 4: 8MM, Sex-Specific Total Prevalent Cases of HIV, All Ages, N, 2013

Figure 5: 8MM, Age-Standardized Total Prevalence of HIV, All Ages, N, 2013

Figure 6: 8MM, Cases of HIV in Pregnant Women Among the Total Prevalent Cases of HIV in Women, N, 2013 and 2023

Figure 7: Japan, 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, All Ages, N, 2013–2023

Figure 8: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Men and Women, N, 2013

Figure 9: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2013

Figure 10: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV, All Ages, N, 2013

Figure 11: Japan, Cases of HIV in Pregnant Women Among Diagnosed Prevalent Cases of HIV in Women, N, 2013 and 2023

Figure 12: HIV-1 Disease Management Flowchart

Figure 13: HIV Therapeutics – Phase II and III Clinical Trials by Country, 2014

Figure 14: HIV Phase II/Phase III Pipeline, 2014

Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2013–2023

Figure 16: Potential Clinical and Commercial Positioning of Quad 2

Figure 17: Potential Clinical and Commercial Positioning of Darunavir/Cobicistat/Emtricitabine/TAF

Figure 18: Potential Clinical and Commercial Positioning of Emtricitabine/TAF

Figure 19: Potential Clinical and Commercial Positioning of Dutrebis

Figure 20: Potential Clinical and Commercial Positioning of Doravirine

Figure 21: Company Portfolio Gap Analysis in HIV, 2013–2023

Figure 22: Global Sales for HIV Therapeutics by Country, 2013–2023

Figure 23: Global Sales for HIV Therapeutics by Drug Class, 2013–2023

Figure 24: Sales for HIV Therapeutics in the US by Drug Class, 2013–2023

Figure 25: Sales for HIV Therapeutics in the 5EU by Drug Class, 2013–2023

Figure 26: Sales for HIV Therapeutics in the 5EU by Country, 2013–2023

Figure 27: Sales for HIV Therapeutics in Japan by Drug Class, 2013–2023

Figure 28: Sales for HIV Therapeutics in Brazil by Drug Class, 2013–2023

Figure 29: Sales for HIV Therapeutics in China by Drug Class, 2013–2023

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports